Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy
while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative …

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Methods: ACOSOG Z0011 prospectively examined overall survival of patients with SLN
metastases undergoing breast-conserving therapy randomized to undergo ALND after …

Heart failure is a common, costly, and debilitating syndrome that is associated with a highly
complex drug regimen, a large number of comorbidities, and a large and often disparate …

Poorly water-soluble drugs are frequently encountered and present a most challengeable
difficulty in pharmaceutical development. Poor solubility of drugs can lead to suboptimal …

Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive
chemotherapy. This review provides an up-to-date assessment of the patient and cost …

Breast cancer is the most common cause of cancer and cancer death worldwide. Although
most patients present with localized breast cancer and may be rendered disease-free with …